An Open-Label, Phase 2a Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
Latest Information Update: 01 Jul 2025
At a glance
- Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
- Indications Depression; Major depressive disorder
- Focus Adverse reactions
- Sponsors Beckley Psytech
Most Recent Events
- 25 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 20 May 2025 According to a Beckley Psytech media release, Data from the study will be used to planning of Phase 3 study.
- 20 May 2025 Results presented in the Beckley Psytech Media Release.